These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 24485398

  • 1. Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration--a randomised, double-blind, placebo-controlled, cross-over study.
    Nybäck-Nakell Å, Adamson U, Lins PE, Landstedt-Hallin L.
    Diabetes Res Clin Pract; 2014 Feb; 103(2):286-91. PubMed ID: 24485398
    [Abstract] [Full Text] [Related]

  • 2. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Forst T, Anastassiadis E, Diessel S, Löffler A, Pfützner A.
    Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Sep; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 5. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients.
    Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S.
    Diabet Med; 2001 Oct; 18(10):828-34. PubMed ID: 11678974
    [Abstract] [Full Text] [Related]

  • 6. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW, Baggesen LM, Søgaard M, Pedersen L, Nørrelund H, Buhl ES, Haase CL, Johnsen SP.
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [Abstract] [Full Text] [Related]

  • 7. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [Abstract] [Full Text] [Related]

  • 8. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, D'Angelo A, Maffioli P.
    Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
    [Abstract] [Full Text] [Related]

  • 9. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
    Sonnenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, DeChemey GS, Mullican WS, Stonesifer LD.
    Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
    [Abstract] [Full Text] [Related]

  • 10. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
    Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, Cicero AF.
    Diabetes Obes Metab; 2006 Mar; 8(2):197-205. PubMed ID: 16448524
    [Abstract] [Full Text] [Related]

  • 11. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE, Matthews DR.
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A, Schöndorf T, Tschöpe D, Lobmann R, Merke J, Müller J, Lehmann U, Fuchs W, Forst T.
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [Abstract] [Full Text] [Related]

  • 17. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [Abstract] [Full Text] [Related]

  • 18. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.
    Rosenstock J, Samols E, Muchmore DB, Schneider J.
    Diabetes Care; 1996 Nov; 19(11):1194-9. PubMed ID: 8908379
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G, Issa M, Vlajnic A.
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.